financetom
Market
financetom
/
Market
/
Sebi fines brokerage firm, Anand Rathi for violating stock broker norms
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sebi fines brokerage firm, Anand Rathi for violating stock broker norms
Nov 27, 2018 8:31 PM

Markets regulator Sebi on Tuesday fined brokerage house Anand Rathi Rs 1 lakh for violating stock broker norms by transferring funds from the client's account to own account and vice versa on several occasions.

Share Market Live

NSE

In an order, the regulator said that Anand Rathi Shares and Stock Brokers has mixed-up client's funds with its own funds and vice versa and thereby acted in contravention of Sebi (Stock Brokers and Sub-Brokers) Regulations.

The regulator had outlined strict segregation of client's funds, member account's funds and transfer of funds is permitted as an exception under specific instances.

However, the scheme of arrangement regarding transfer of money made by the Anand Rathi is not in accordance with the permissible conditions under the stock brokers norms which makes it liable for monetary penalty, Sebi noted.

Accordingly, the Securities and Exchange Board of India (Sebi) imposed a fine on the firm.

In a separate order, Sebi has levied a total penalty of Rs 5 lakh on four persons for failing to make disclosure about change in their shareholding in SMS Techsoft Ltd within the required timeline.

The persons facing penalties are Kirtikumar Rasiklal Shah, Alkaben Kirtibhai Shah, Karan Kirtibhai Shah and Kewal Kirtikumar Shah.

According to Sebi, these four persons, who were acting in concert, collectively acquired over 39 lakh shares of the company, which resulted in cumulative change in their shareholding.

However, they failed to mandatory disclosure about this as required under SAST (Substantial Acquisition of Shares & Takeovers) Regulations to the company and BSE.

First Published:Nov 28, 2018 5:31 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Gold Looks to Test a Record High as the Dollar and Yields Ease
Update: Gold Looks to Test a Record High as the Dollar and Yields Ease
Jul 22, 2025
02:00 PM EDT, 07/22/2025 (MT Newswires) -- (Updates prices.) Gold rose to a five-week high early on Tuesday as it looks to challenge a record high on a weak dollar and falling treasury yields. Gold for August delivery was last seen up US$37.40 to US$3,443.80 per ounce, the highest since the metal's record high of US$3,452.80 set on June 13....
US STOCKS-Wall Street mixed; GM slumps as tariffs bite
US STOCKS-Wall Street mixed; GM slumps as tariffs bite
Jul 22, 2025
(Updates with details of afternoon trading) * Tariffs take $1 billion bite from GM earnings, shares tumble * RTX down after cutting 2025 profit forecast * S&P 500 +0.01%, Nasdaq -0.36%, Dow +0.23% By Noel Randewich and Pranav Kashyap July 22 (Reuters) - Wall Street shares were mixed on Tuesday, with steep losses in General Motors ( GM ) and...
Corporate Earnings, Trade Developments Leave Equity Markets Mixed Intraday
Corporate Earnings, Trade Developments Leave Equity Markets Mixed Intraday
Jul 22, 2025
02:04 PM EDT, 07/22/2025 (MT Newswires) -- US benchmark equity indexes were mixed intraday as traders parsed the latest set of corporate earnings and updates around trade developments. The Dow Jones Industrial Average was up 0.3% at 44,460.8 after midday Tuesday, while the S&P 500 rose 0.1% to 6,310.1. The Nasdaq Composite fell 0.3% to 20,911.9. The S&P 500 and...
Top Midday Decliners
Top Midday Decliners
Jul 22, 2025
02:36 PM EDT, 07/22/2025 (MT Newswires) -- Wedbush Securities downgraded Replimune Group ( REPL ) to neutral from outperform, while adjusting its price target to $4 from $19. Replimune ( REPL ) could need a significant restructuring in the near term to accommodate changes to the study of RP1 in combination with nivolumab in advanced melanoma, Wedbush said in a...
Copyright 2023-2025 - www.financetom.com All Rights Reserved